Acetaminophen Use in Pregnancy: A Comparison of Self-Reported Intake with Maternal and Newborn Biomarker Measures

Pengfei Guo, Caroline H. Johnson, Hong Yan, Jingyuan Xiao, Courtney Dennis, Kerry A. Pierce, Andrew T. DeWan, Zeyan LiewClinical 2025 · DOI

Introduction

Acetaminophen (APAP) is the most common medication taken during pregnancy. However, its long-term impact on fetal neurological and reproductive development remains a subject of intense debate. A primary hurdle in studying these effects is exposure misclassification. Most epidemiological studies rely on maternal recall, which is subject to bias, or single biological "spot" samples. Because APAP and its metabolites have short half-lives (less than 4 hours), a single test may miss regular users. This study investigates whether self-reported frequent use correlates with internal doses reaching the fetus and assesses the stability of these biomarkers in samples stored for over two decades.

Methods and Datasets

Researchers utilized data from the Nutrition in Pregnancy (NIP) Study, a cohort of 2,291 individuals recruited between 1996 and 2000. For this pilot study, 30 pregnancies were selected and categorized into three groups:

  1. Non-users: No reported APAP use in the 1st or 3rd trimester.
  2. Frequent T1 users: >14 days of use per month in the 1st trimester.
  3. Frequent T3 users: >14 days of use per month in the 3rd trimester.

Matched pairs of maternal mid-pregnancy urine and umbilical cord serum were analyzed using Liquid Chromatography-Mass Spectrometry (LC-MS). The analysis targeted the parent compound (APAP), the major inactive metabolite (APAP-gluc), and the oxidative byproduct (APAP-cys).

Key Results

The study validated that maternal self-reports of frequent use in late pregnancy align closely with biological markers.

Log-10 abundance of APAP and its metabolites in maternal urine and cord serum across self-reported use groups.

Key findings include:

  • Validation of Self-Reporting: Cumulative days of use in the 3rd trimester (T3) were strongly correlated with cord serum metabolites (r > 0.70). T3 frequent users had significantly higher metabolite levels than non-users (p < 0.05).
  • The "Time Gap" in Biomarkers: While T3 reports correlated well with cord blood (collected at birth), T1 reports did not correlate with mid-pregnancy urine samples. This suggests that biological samples primarily capture intake close to the time of collection.
  • Ubiquitous Exposure: APAP was detected in 100% of maternal urine and cord serum samples, including those from "non-users." This indicates low-level environmental exposure, possibly through water or food.
  • Fetal Metabolism: Cord blood showed lower levels of APAP-gluc compared to maternal urine, supporting the theory that the fetal liver is less efficient at glucuronidation, potentially increasing reliance on oxidative pathways.

Discussion and Stability

A significant finding for longitudinal research is that APAP metabolites remain detectable and quantifiable in human samples stored at -80°C for over 20 years. This confirms the utility of biobanked samples for retrospective exposure assessment.

While the study is limited by a small sample size (n=30) and a lack of second-trimester data, it demonstrates that self-reports are an efficient and valid tool for identifying frequent users. Future research should utilize larger cohorts and repeated self-reports supplemented by biological measures to further minimize exposure misclassification.

Summary updated

BibTeX
@inproceedings{guo2025acetaminophen,
  author = {Pengfei Guo and Caroline H. Johnson and Hong Yan and Jingyuan Xiao and Courtney Dennis and Kerry A. Pierce and Andrew T. DeWan and Zeyan Liew},
  title = {{Acetaminophen Use in Pregnancy: A Comparison of Self-Reported Intake with Maternal and Newborn Biomarker Measures}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.2147/clep.s484953},
}
Figure